Press Releases

BASF Completes Mechanical Construction of Acrylics Complex at Zhanjiang Verbund Site

BASF Reaches Major Construction Milestone with Mechanical Completion of Acrylics Complex at Zhanjiang Verbund Site BASF has successfully reached a pivotal milestone in the development of its world-class Zhanjiang Verbund site in China, announcing the mechanical completion of the first…

Read MoreBASF Completes Mechanical Construction of Acrylics Complex at Zhanjiang Verbund Site

Investment in Australia’s Licella to Expand Oil Conversion and Diversify Feedstocks

Mitsubishi Chemical Group Invests in Licella to Advance Oil Conversion Technology and Expand Sustainable Feedstock Solutions Mitsubishi Chemical Group (MCG) has announced a strategic investment in Licella Holdings, an Australian company known for its proprietary Cat-HTR™ (Catalytic Hydrothermal Reactor) technology.…

Read MoreInvestment in Australia’s Licella to Expand Oil Conversion and Diversify Feedstocks
New Study Finds Health-Boosting Compounds

New Study Finds Health-Boosting Compounds in California Almonds

New Research Uncovers Powerful Health-Promoting Compounds in California Almonds New Research Uncovers Powerful Health-Promoting Compounds in California Almonds California almonds—already known for their heart-healthy and nutrient-rich profile—may be even more beneficial than previously thought. Brightseed, a pioneering company in nutritional…

Read MoreNew Study Finds Health-Boosting Compounds in California Almonds
Agenus’ BOTBAL Shows 42% 2-Year Survival

Agenus’ BOT/BAL Shows 42% 2-Year Survival in MSS CRC, Moves Toward FDA Registration

Agenus’ BOT/BAL Combo Delivers 42% Two-Year Survival in MSS Colorectal Cancer: Phase 3 Trial Aligned with FDA Agenus Inc., a pioneer in immuno-oncology, announced compelling new clinical results and regulatory progress for its combination therapy of botensilimab and balstilimab (BOT/BAL).…

Read MoreAgenus’ BOT/BAL Shows 42% 2-Year Survival in MSS CRC, Moves Toward FDA Registration
CorFlow’s MOCA-II Trial Approved by FDA to Advance Heart Attack Treatment

CorFlow’s MOCA-II Trial Approved by FDA to Advance Heart Attack Treatment

FDA Approves CorFlow’s MOCA-II IDE Pivotal Trial to Advance Breakthrough Heart Attack Technology CorFlow Therapeutics AG, a Swiss-based medtech innovator specializing in cardiovascular care and microvascular disease, has reached a major milestone in the development of its cutting-edge heart attack…

Read MoreCorFlow’s MOCA-II Trial Approved by FDA to Advance Heart Attack Treatment